CTOs on the Move

ValGenesis

www.valgenesis.com

 
As a pioneer in the development of automated validation software solutions, ValGenesis leads the way with a unique paperless validation process that tracks the validation status of any GxP system in real time. With years of development and refinement in place, ValGenesis is the first to offer users real-time paperless validation via electronic execution thereby minimizing ineffectiveness and maximizing efficiency. ValGenesis automates and manages the validation life cycle and provides real time validation status of any system corporate wide.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.valgenesis.com
  • 395 Oyster Point Boulevard Suite 228
    South San Francisco, CA USA 94080
  • Phone: 510.445.0505

Executives

Name Title Contact Details
Mike Hicks
Chief Technology Officer Profile

Funding

ValGenesis raised $24M on 05/04/2021

Similar Companies

Hapbee

Hapbee is the only wearable wellness technology that delivers the molecular signature of compounds (like melatonin, caffeine, CBD and many others) through magnetic waves - so you can experience the benefits digitally without any of the side effects. It puts you in control of your wellness.

M3 Biotechnology

M3 is a biopharmaceutical company focused on development of therapeutics to address Alzheimer`s, Parkinson`s and Neurodegeneration.

ApoCell

ApoCell is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

On Target Laboratories

Our illuminating molecules enhances the doctors ability to see disease tissue clearly improving their ability to treat cancer, autoimmune and other diseases.

Be Biopharma

Be Biopharma is a leader in developing B cells as medicines, treating disease with the human body`s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, allogeneic, re-dosable, and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., Be Biopharma is re-imagining medicine based on the power of B cell therapy. Be Bio was founded in October 2020 by Longwood Fund with a $52 million Series A investment led by Atlas Ventures and RA Capital, joined by Alta Partners and Takeda Ventures.